RPF2 AAV Expression With Destabilization Domains for Retinal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Long-term expression of neurotrophic factors like LIF and CNTF can be detrimental to retinal function and may promote inflammation, posing a challenge in treating retinal degenerative disorders.
Innovation Solution
Development of adeno-associated virus (AAV)-based expression vectors encoding fusion proteins with a destabilization domain (DD), allowing controlled expression of therapeutic proteins through interaction with a small molecule like trimethoprim, thereby modulating the expression of neurotrophic factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurotrophic factors (LIF, CNTF) are highly expressed to protect photoreceptors, then photoreceptor protection is improved, but retinal inflammation and detrimental effects worsen
Solution Approach 1:
The patent applies dynamics by making the expression of neurotrophic factors controllable and reversible through the destabilization domain system. The therapeutic protein expression can be dynamically adjusted by adding or removing small molecule ligands, allowing the system to transition between active and inactive states as needed, thereby protecting photoreceptors when required while avoiding chronic inflammation.
Solution Approach 2:
The patent changes the stability parameter of the therapeutic protein by fusing it with a destabilization domain that responds to small molecule ligands. This parameter change allows precise control over protein half-life and expression levels, enabling therapeutic benefit while minimizing harmful effects associated with sustained high-level expression.
2Duration of action of stationary object
If therapeutic proteins are continuously expressed to maintain retinal function, then neuroprotection is improved, but adverse effects worsen
Solution Approach 1:
The patent implements periodic action by enabling intermittent expression of therapeutic proteins through inducible control systems. Expression can be activated periodically by administering small molecule ligands and deactivated by withdrawing them, providing neuroprotection during active periods while allowing the system to reset and avoid cumulative adverse effects.
Solution Approach 2:
The patent introduces small molecule ligands as intermediaries that mediate between the therapeutic protein and its expression control. These ligands bind to the destabilization domain to modulate protein stability, providing a controllable mechanism to achieve desired duration of action while minimizing adverse effects through precise temporal control.
3Productivity
If AAV vectors are used to deliver therapeutic genes, then delivery efficiency is improved, but controlled expression capability worsens
Solution Approach 1:
The patent merges the high delivery efficiency of AAV vectors with the controllable expression capability of destabilization domain systems. By combining these two approaches, the therapeutic gene is efficiently delivered to retinal cells via AAV while simultaneously enabling precise control over protein expression levels and duration through small molecule-responsive destabilization domains.
Solution Approach 2:
The patent creates a composite expression system combining AAV vector delivery machinery with destabilization domain control elements. This composite approach integrates the advantages of both systems: the efficient cellular delivery and long-term persistence of AAV vectors with the inducible and reversible expression control of small molecule-responsive protein domains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables safe and effective delivery and regulation of therapeutic proteins, maintaining or improving retinal function without adverse effects, as demonstrated by reduced inflammation and preservation of retinal morphology.
Implementation Method 1
a DD (e.g., DHFR protein or a fragment thereof) is capable of being bound by trimethoprim (TMP)
Data Source
AI summary
In some aspects, the disclosure relates to compositions and methods useful for maintaining or improving retinal function and/or morphology. The disclosure is based, in part, on isolated nucleic acids encoding certain neurotrophic factors (e.g., leukemia inhibitory factor (LIF), etc.) and gene therapy vectors (e.g., recombinant adeno-associated virus (rAAV) vectors) encoding the same. In some embodiments, isolated nucleic acids and gene therapy vectors described by the disclosure are useful for treatment of certain diseases or disorders of the eye, for example retinal degeneration, retinitis pigmentosa (RP), age-related macular degeneration (AMD), glaucoma, etc.